Noubar Afeyan defends Moderna's cancer trial data after stock slide

Name: Noubar Afeyan defends Moderna's cancer trial data after stock slide
Uploaded: 2026-10-26T20:23:48Z
Duration: 2 min 23 s
Description: Moderna co-founder and Chairman Noubar Afeyan joins Liz Claman to discuss the market's reaction to Moderna's melanoma trial data. Despite a positive trial showing a 42% reduction in recurrence or death when combined with Merck's Keytruda, the stock tumbled following a premature release of the study's results.

The Claman Countdown · FBN · Aired Mon, Oct 26 · 2m 23s

Watch Now

Already a subscriber?

Moderna co-founder and Chairman Noubar Afeyan joins Liz Claman to discuss the market's reaction to Moderna's melanoma trial data. Despite a positive trial showing a 42% reduction in recurrence or death when combined with Merck's Keytruda, the stock tumbled following a premature release of the study's results.